查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863422

生物製造领域病毒检测与定量市场：按产品、技术、应用、最终用户和样品类型划分－2025-2032年全球预测

Biomanufacturing Viral Detection & Quantification Market by Product, Technology, Application, End User, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，生物製造领域的病毒检测和定量市场将成长至 56.3 亿美元，复合年增长率为 8.67%。

关键市场统计数据
基准年 2024 28.9亿美元
预计年份：2025年 31.4亿美元
预测年份 2032 56.3亿美元
复合年增长率 (%) 8.67%

深入探讨先进的病毒检测和定量技术如何成为现代生物製造品质和营运韧性的基础

随着精准检测技术从实验室走向受监管的生产环境，支持病毒检测和定量分析的生物製造环境正在迅速发展。分子诊断技术的进步，结合自动化和数位分析技术，能够实现更严格的污染控制、更快的产品放行流程，并加强上游工程下游品质系统之间的协作。各组织机构日益认识到，侦测和定量技术不仅是实验室工具，更是保障产品安全、优化批次週转和满足更高监管要求的策略性槓桿。

在实务中，这意味着跨职能团队必须协调检测方法的选择、样本处理流程和资料管治，才能获得可重复且审核的结果。实验室负责人必须平衡通量和灵敏度，根据既定标准检验新型平台，并在不影响可追溯性的前提下设计可扩展的工作流程。此外，次世代定序、数位PCR、免疫检测平台和基于CRISPR的检测工具的融合，不仅拓展了分析选择，为加快生物製品上市速度创造了机会，同时也对生物资讯学、检测合格和污染风险管理提出了新的要求。

随着生物技术研发管线向基因疗法、病毒载体和复杂生物製药等领域多元化发展，检测和定量技术将日益影响生产週期、监管申报和病患安全预期。因此，对于致力于品质和营运韧性的现代生物製造企业而言，策略性地采用这些技术至关重要。

CRISPR、数位PCR、次世代定序和自动化技术的整合正在从根本上重塑病毒检测工作流程、品质控制策略和监管准备。

技术创新、监管重点和生物製造领域不断演变的应用案例的融合，正在重塑病毒检测和定量格局。诸如基于 CRISPR 的检测平台和数位 PCR 等快速成熟的技术，能够以适用于高纯度环境的形式提供单分子灵敏度；而次世代定序平台则提供全面的基因组分析能力，从而革新根本原因分析和病毒安全性检测。同时，免疫检测技术的改进和侧向层析技术的创新，持续为常规监测提供经济高效的高通量筛检方案。

随着产业领导企业逐渐抛弃传统方法，他们正将仪器、试剂和软体整合到以自动化、资料完整性和可追溯性为优先的整合工作流程中。这项转变的驱动力在于监管机构日益重视健全的病毒安全计画和可追溯的分析记录，从而鼓励对检验的平台和标准化通讯协定进行投资。同时，个人化医疗和基因疗法的兴起也加速了高灵敏度分子检测工具的应用，因为它们引入了复杂的样本基质和低丰度靶标，对传统检测方法提出了挑战。

这些变革共同推动了一种新的营运模式，在这种模式下，分析决策与製造设计、品管策略和供应链规划紧密结合。那些透过投资早期验证、多学科培训和整合分析来利用这些变革的组织，将能够降低风险、提高批次放行效率，并在日益严格的法规环境下保持合规性。

评估美国分级关税对关键资产采购、供应商资格认证和供应链韧性的营运和策略影响

美国将于2025年开始实施的累积关税，使病毒检测和定量所需的仪器、试剂和专用耗材的筹资策略变得更加复杂。这些关税提高了进口诊断平台和某些试剂的相对成本，迫使采购团队重新评估其供应商组合、库存政策和资格认证流程。因此，製造商和实验室需要在短期成本压力与维持检验的工作流程和关键材料不间断供应之间寻求平衡。

为此，各组织正采取多种缓解措施。我们看到，各组织正加快对符合性能和监管文件要求的替代供应商（例如区域製造商和契约製造製造商）的资格认证。我们也看到，各组织正致力于重新设计高风险耗材的供应链合同，以纳入更长的前置作业时间和战略库存缓衝，同时优先考虑那些提供灵活交货条款的合同。此外，各组织越来越关注透过试剂形式整合和平台整合来减少需要跨境运输的SKU种类，这可以简化关税合规流程并降低物流成本。

从策略角度来看，关税导致的成本转移迫使产业相关人员加强供应商检验流程、扩大技术转移能力，并投资于能够容纳在地采购试剂的模组化平台。中期来看，这些调整可能有助于减少对单一供应来源的依赖并提高韧性，但短期内，需要谨慎的变更管理、检验计划以及相关人员的协作，以避免对生产计划和产品品质保证造成干扰。

将仪器、试剂生态系统、技术、应用、最终用户和检体类型连结起来，进行全面的細項分析，从而实现策略性的检测选择和采购。

产品细分洞察表明，决策越来越依赖分析能力与特定应用需求的匹配。仪器和系统涵盖 CRISPR 检测系统、数位 PCR 系统、免疫检测分析仪、次世代定序平台、即时PCR系统和聚合酵素连锁反应热迴圈仪，每种产品在灵敏度、通量和整合度方面都各具特色。试剂和套件包括免疫检测试剂、NGS样品製备试剂套件、PCR 预混液、RNA 萃取试剂套件和定序试剂，所有这些都是确保检测一致性和批间可重复性的关键要素。软体和服务则透过提供资料管理、演算法解读和检验支持，完善了产品体系，满足了受监管环境的需求。

从技术面来看，CRISPR技术、免疫检测、次世代定序和聚合酵素链锁反应（PCR）各有优缺点。免疫检测包括化学发光免疫检测、化学冷光免疫吸附试验（ELISA）和横向流动化验等多种方法，其优点在于高通量和易用性，适用于筛检。新一代定序方法，例如Illumina测序、Ion Torrent测序和奈米孔测序，可提供详细的基因组信息，用于表征和根本原因分析。聚合酵素链锁反应技术涵盖了从传统PCR到数位PCR和即时PCR等多种类型，每种技术都针对不同的灵敏度和定量需求。

应用细分突显了基因治疗品管、研究应用、疫苗开发、病毒量监测和病毒安全性检测等用例，这些应用需求直接决定了合适的产品和技术组合。最终用户，包括学术研究机构、受託研究机构(CRO)、诊断实验室、医院/诊所和製药/生物技术公司，各自拥有独特的营运限制和监管要求，这些因素影响采购标准。此外，检体类型，例如血液/血浆、环境样本、呼吸道样本和组织样本，也带来了分析方面的挑战，这些挑战决定了提取通讯协定、检测方法的选择和验证途径。理解这些相互关联的细分层面，有助于制定更有针对性的平台选择和筹资策略，以满足绩效要求和监管规定。

美洲、欧洲、中东和非洲以及亚太地区不同的区域驱动因素如何影响侦测能力的取得、检验和供应链策略？

区域趋势正在影响病毒检测和定量能力的需求模式和供应链策略。在美洲，创新中心和密集的合约研发生产机构 (CDMO) 网路正在推动对高通量平台、先进定序和高精度定量方法的需求，以支援生物製药研发管线。该地区还优先考虑快速明确的监管政策和营运扩充性，这影响供应商的选择和验证时间表。

在欧洲、中东和非洲地区，强大的公共卫生基础设施和卓越的学术水平，以及监管协调方面的挑战，持续推动对研究级和符合GMP规范的分析解决方案的需求。该地区的机构正在投资模组化实验室自动化和协同检验框架，以满足多样化的监管要求，同时保持跨境互通性。在亚太地区，产能的快速扩张、不断增长的生物製药生产基地以及对本地生产能力的大规模投资，催生了对经济高效的试剂、适应性强的平台和可扩展软体解决方案的需求。亚太地区的供应链策略日益重视在地采购和区域伙伴关係，以优化成本并降低受国际贸易政策波动的影响。

这些区域差异总体上会影响供应商网路设计、验证策略以及国内采购与国际采购等方面的决策。监管要求和基础设施成熟度的区域差异要求製造商和实验室根据当地的实际情况调整分析策略，以确保专案的连续性、合规性和时效性。

仪器製造商、试剂专家和平台创新者之间的策略竞争正在影响伙伴关係、验证服务和长期采购决策。

病毒检测和定量生态系统的竞争动态呈现成熟仪器供应商、试剂专家和新兴平台创新者并存的态势。大型仪器製造商持续投资于平台融合，整合分子、定序、免疫检测和其他检测方式，以提供更广泛的分析功能，从而吸引科研和受监管的生产客户。同时，专业的试剂和套件供应商则专注于配方一致性、批次控制和法规文件，以支援GMP环境下的检验工作流程。Start-Ups和规模化企业正不断突破界限，利用基于CRISPR的检测方法、改进的奈米孔定序技术和软体驱动的分析技术，力求更快解决问题并提供更具实用价值的资料集。

硬体供应商、试剂生产商和软体开发人员之间的合作日益普遍，从而能够提供端到端的解决方案，降低终端用户的使用复杂性。与受託研究机构(CRO) 和合约开发与生产组织 (CDMO) 建立策略合作伙伴关係，也有助于进行实际验证工作，并加速产品在商业生产环境中的部署。能够提供全面验证方案、快速回应的技术支援和云端资料管理的供应商，在客户评估总体拥有成本和长期合规性时，往往能够获得竞争优势。

最终，那些能够平衡平台性能和可维护性、监管支援以及供应连续性的公司，将最有希望赢得长期合约。能够快速回应变更管理请求、提供灵活的供应安排并展现出对互通软体生态系统投资的供应商，将更能成功地满足生物製造利害关係人不断变化的需求。

针对生物製造企业领导者，提出具体且切实有效的建议，以加强检测验证、供应商多元化、自动化互通性和监管资料完整性。

产业领导者应优先考虑一系列切实可行的倡议，以提升病毒检测和定量项目的分析稳健性、供应链韧性和监管合规性。首先，建立跨职能的管治，协调品管、生产製造和分析开发团队，可以打破部门壁垒，加速检测方法选择、变更管理和技术转移的决策。儘早将负责人融入检验计划，可确保侦测效能标准符合放行要求，并减少后续环节可能出现的意外问题。

其次，各机构应使其合格供应商名单多元化，为关键试剂和耗材寻求冗余，并建立清晰的重新认证流程，以最大限度地减少生产中断。策略性库存管理，结合基于情境的供应商连续性压力测试，可以在不增加储存成本的情况下降低营运风险。第三，投资于跨平台互通性和模组化自动化可以减少仪器和试剂规格切换时的摩擦，从而能够灵活应对供应衝击和法规变化。透过检验的软体、完善的审核追踪和标准化的报告范本来确保资料完整性，可以进一步提高监管可信度和审核准备度。

最后，透过与外部实验室和合约机构合作，提升检测能力，并在关键放行检测中逐步引入数位PCR和标靶定序等灵敏度技术，将提高检测灵敏度和诊断解析度。这些建议的综合实施将建构一个稳健、合规且有效率的分析基础设施，在保障产品品质的同时，加速专案开发进程。

采用严谨的混合调查方法，结合相关利益者访谈、技术文献综述、监管协调和基于情境的供应链分析。

本分析的调查方法系统地整合了定性和定量证据，以提供可靠且具有实践意义的观点。关键资讯是透过对实验室主任、品质保证人员、采购经理和技术专家的访谈收集的，从而深入了解平台性能、验证挑战和供应商趋势。这些第一手资料经过综合分析，旨在识别不同终端使用者和应用领域面临的通用挑战和推动因素。

我们从同行评审文献、监管指导文件、技术白皮书和公开产品文件中收集了二手信息，以检验技术能力和典型应用场景。分析还包括基于场景的供应链评估，以根据行业标准的供应连续性实践评估关税变化和供应商中断可能造成的营运影响。透过将定性研究结果与已记录的产品规格、监管要求以及受法规环境中常用的验证通讯协定进行交叉检验，确保了分析的严谨性。

在整个研究过程中，我们始终强调假设的透明度、记录支持论点的可追溯证据，以及与生物製造企业面临的实际实施限制保持一致。这种混合方法确保了结论和建议既有证据支持，也能直接应用于商业决策。

权威的综合分析重点阐述了综合检测策略、供应商韧性和先进分析技术如何决定生物製造的成功和监管准备。

总之，病毒检测和定量不再是辅助性活动，而是生物製造品质和运作策略的核心要素。灵敏的分子工具、自动化工作流程和先进分析技术的整合，正在切实改善污染控制、批次放行流程和监管可追溯性。同时，贸易政策趋势和日益复杂的供应链也要求企业加强对供应商合格、灵活的验证方案和互通平台的投资，以保障业务永续营运。

采取策略性方法的组织——结合跨职能管治、多元化采购、有针对性地应用敏感技术以及检验的资料管理系统——将更有利于管理风险并加快产品开发週期。随着技术的不断发展，持续学习、伙伴关係主导的检验活动以及情境规划对于维持合规性和竞争优势至关重要。最终，能否将分析能力转化为稳健的生产实践，将决定哪些组织能够持续为患者提供高品质的生物製药和先进疗法。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合数位PCR和次世代定序以提高大规模生物製程中病毒量定量分析的准确性
  • 引入基于人工智慧的即时病毒去除过程监控，以降低生物製造过程中的生物安全风险
  • 引入配备线上病毒检测感测器的连续流生物反应器，以优化疫苗生产的规模化生产。
  • 为实现新型快速分子检测方法在全球核准用于病毒污染监测，并正在进行监管协调工作。
  • 开发一种基于CRISPR技术的多重检测方法，用于同时检测生物製药中的多种病毒污染物
  • 基于微流体的现场病毒定量诊断平台在分散式生技药品生产监测的应用进展

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 生物製造病毒检测和定量市场（按产品划分）

  • 设备和系统
    • CRISPR检测系统
    • 数位PCR系统
    • 免疫检测分析仪
    • 次世代定序平台
    • 即时PCR系统
    • 聚合酵素连锁反应热迴圈仪
  • 试剂和套件
    • 免疫检测试剂
    • 次世代定序样品製备套件
    • PCR 预混液
    • RNA萃取试剂套件
    • 定序试剂
  • 软体和服务

9. 生物製造病毒检测和定量市场（按技术划分）

  • CRISPR技术
  • 免疫检测
    • 化学冷光免疫检测
    • ELISA
    • 横向流动化验
  • 次世代定序
    • Illumina定序
    • 离子流定序
    • 奈米孔定序
  • 聚合酵素链锁反应
    • 常规PCR
    • 数位PCR
    • 即时PCR

第十章 生物製造领域病毒检测与定量市场（依应用划分）

  • 基因治疗的品管
  • 研究用途
  • 疫苗研发
  • 病毒量监测
  • 病毒安全性测试

第十一章 生物製造领域病毒检测与定量市场（依最终用户划分）

  • 学术和研究机构
  • CRO（受託研究机构）
  • 诊断实验室
  • 医院和诊所
  • 製药和生物技术公司

12. 生物製造领域病毒检测与定量市场（依检体类型划分）

  • 血液/血浆
  • 环境样品
  • 呼吸道检体
  • 组织样本

13. 各地区生物製造领域病毒检测与定量市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 生物製造领域病毒检测与量化市场（依产业划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国生物製造领域病毒检测与量化市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Merck KGaA
    • Roche Holding AG
    • QIAGEN NV
    • Illumina, Inc.
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.
    • PerkinElmer, Inc.
    • Sartorius AG
Product Code: MRR-5C6F41F5AF8D

The Biomanufacturing Viral Detection & Quantification Market is projected to grow by USD 5.63 billion at a CAGR of 8.67% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.89 billion
Estimated Year [2025] USD 3.14 billion
Forecast Year [2032] USD 5.63 billion
CAGR (%) 8.67%

An in-depth introduction to how advanced viral detection and quantification technologies are becoming foundational to modern biomanufacturing quality and operational resilience

The biomanufacturing environment that supports viral detection and quantification is undergoing rapid evolution as precision assays move from research benches into regulated production environments. Advances in molecular diagnostics, coupled with automation and digital analytics, are driving more robust contamination control, accelerated product release workflows, and tighter integration between upstream and downstream quality systems. Organizations increasingly recognize that detection and quantification technologies are not discrete laboratory tools but strategic levers to protect product safety, optimize batch turnaround, and satisfy intensified regulatory expectations.

In practice, this means cross-functional teams must harmonize assay selection, sample handling procedures, and data governance to achieve reproducible, auditable results. Lab leaders need to balance throughput with sensitivity, validate novel platforms against established benchmarks, and design workflows that scale without compromising traceability. Moreover, the convergence of next-generation sequencing, digital PCR, immunoassay platforms, and CRISPR-based detection tools is expanding analytical choices, creating opportunities to reduce time-to-release for biologics while demanding new competency in bioinformatics, assay qualification, and contamination risk management.

As biotechnology pipelines diversify into gene therapies, viral vectors, and complex biologics, detection and quantification practices will increasingly influence manufacturing cycle time, regulatory submissions, and patient safety expectations. Therefore, a strategic introduction to these technologies frames them as essential infrastructure for any modern biomanufacturing organization committed to quality and operational resilience.

How convergence of CRISPR, digital PCR, next-generation sequencing, and automation is fundamentally reshaping viral detection workflows, quality strategies, and regulatory readiness

The landscape of viral detection and quantification is being redefined by a confluence of technological innovation, regulatory emphasis, and evolving use cases within biomanufacturing. Rapidly maturing technologies such as CRISPR-based detection platforms and digital PCR are delivering single-molecule sensitivity in formats suitable for high-integrity environments, while next-generation sequencing platforms provide comprehensive genomic resolution that transforms root-cause analysis and viral safety testing. At the same time, immunoassay refinements and lateral flow innovations continue to offer cost-effective, high-throughput screening options for routine surveillance.

Transitioning from legacy approaches, industry leaders are integrating instruments, reagents, and software into cohesive workflows that prioritize automation, data integrity, and traceability. This shift is reinforced by regulatory agencies placing greater emphasis on robust viral safety programs and traceable analytical records, prompting investments in validated platforms and standardized protocols. Simultaneously, the rise of personalized medicines and gene therapies has introduced complex sample matrices and low-abundance targets that challenge conventional detection modalities, thereby accelerating adoption of highly sensitive molecular tools.

Taken together, these transformative shifts are driving a new operating paradigm in which analytical decisions are tightly coupled to manufacturing design, quality control strategies, and supply chain planning. Organizations that harness these shifts through early validation, cross-disciplinary training, and investment in integrated analytics are positioned to reduce risk, improve batch release efficiency, and sustain compliance in an increasingly demanding regulatory environment.

Evaluating the operational and strategic effects of layered United States tariff measures on procurement, supplier qualification, and supply chain resilience for critical detection assets

Cumulative tariff actions originating in the United States in 2025 have introduced layered complexity into sourcing strategies for instruments, reagents, and specialized consumables used in viral detection and quantification. The tariffs have increased the relative cost of imported diagnostic platforms and certain reagent classes, prompting procurement teams to reassess supplier portfolios, inventory policies, and qualification pathways. As a result, manufacturers and laboratories are balancing the trade-offs between near-term cost pressures and the imperative to maintain validated workflows and uninterrupted supply of critical materials.

In response, organizations are pursuing a variety of mitigation approaches. Some are accelerating qualification of alternative suppliers, including regional manufacturers and contract manufacturers that can meet performance and regulatory documentation requirements. Others are redesigning supply chain agreements to include longer lead times and strategic inventory buffers for high-risk consumables while prioritizing contracts with flexible delivery terms. Additionally, there is growing interest in consolidating reagent formats and platform convergence to reduce the diversity of SKUs that require cross-border movement, thereby simplifying compliance with tariff regimes and lowering logistical overhead.

From a strategic perspective, tariff-driven cost shifts are compelling industry stakeholders to strengthen supplier validation processes, expand technical transfer capabilities, and invest in modular platforms that can accommodate locally sourced reagents. Over the medium term, these adaptations may enhance resilience by reducing single-source dependencies, but in the near term they demand careful change control, revalidation planning, and stakeholder alignment to avoid disruptions to manufacturing timelines and product quality assurance.

Comprehensive segmentation insights connecting instruments, reagent ecosystems, technologies, applications, end users, and sample types to strategic assay selection and procurement

Insight into product segmentation reveals that decision-making is increasingly driven by the need to match analytical capability with application-specific requirements. Instrumentation and systems span CRISPR detection systems, digital PCR systems, immunoassay analyzers, next-generation sequencing platforms, real-time PCR systems, and thermal cyclers, each offering distinct performance profiles for sensitivity, throughput, and integration. Reagents and kits encompass immunoassay reagents, NGS library preparation kits, PCR master mixes, RNA extraction kits, and sequencing reagents, all of which are fundamental to assay consistency and lot-to-lot reproducibility. Software and services complete the product landscape by enabling data management, algorithmic interpretation, and validation support necessary for regulated contexts.

From a technology perspective, CRISPR technology, immunoassays, next-generation sequencing, and polymerase chain reaction approaches present divergent strengths and trade-offs. Immunoassays include chemiluminescent immunoassay, ELISA, and lateral flow assay variants that favor throughput and ease of use for screening, while next-generation sequencing modalities such as Illumina sequencing, Ion Torrent sequencing, and nanopore sequencing deliver granular genomic insights for characterization and root-cause analyses. Polymerase chain reaction techniques range from conventional PCR to digital PCR and real-time PCR, with each type serving different sensitivity and quantitation needs.

Application segmentation highlights use cases including gene therapy quality control, research applications, vaccine development, viral load monitoring, and viral safety testing, and these application needs directly influence which product and technology combinations are appropriate. End users such as academic and research institutions, contract research organizations, diagnostic laboratories, hospitals and clinics, and pharmaceutical and biotechnology companies each have distinct operational constraints and regulatory expectations that shape procurement criteria. Finally, sample types including blood and plasma, environmental samples, respiratory samples, and tissue samples impose analytical challenges that determine extraction protocols, assay selection, and validation pathways. Understanding these interconnected segmentation layers enables more targeted platform selection and procurement strategies that align with performance requirements and regulatory obligations.

How distinct regional drivers across the Americas, Europe Middle East & Africa, and Asia-Pacific are shaping procurement, validation, and supply chain strategies for detection capabilities

Regional dynamics are shaping both demand patterns and supply chain strategies for viral detection and quantification capabilities. In the Americas, innovation hubs and a dense network of contract development and manufacturing organizations drive demand for high-throughput platforms, advanced sequencing, and highly quantitative modalities that support complex biologics pipelines. This region also emphasizes rapid regulatory clarity and operational scalability, which influences supplier selection and validation timelines.

In Europe, the Middle East & Africa, regulatory harmonization challenges coexist with pockets of strong public health infrastructure and academic excellence that sustain demand for both research-grade and GMP-compliant analytical solutions. Organizations across this region are investing in modular laboratory automation and collaborative validation frameworks to meet diverse regulatory requirements while maintaining cross-border interoperability. In the Asia-Pacific region, rapid capacity expansion, a growing biopharmaceutical manufacturing base, and significant investment in local manufacturing capability are creating demand for cost-efficient reagents, adaptable platforms, and scalable software solutions. Supply chain strategies in Asia-Pacific often prioritize local sourcing and regional partnerships to optimize costs and reduce exposure to international trade policy shifts.

Taken together, these regional differentiators influence supplier network design, validation strategies, and decisions about onshoring versus international procurement. Because regulatory expectations and infrastructure maturity vary across these geographies, manufacturers and laboratories must align analytical strategies with regional operational realities to ensure continuity, compliance, and time-sensitive program delivery.

Strategic competitive dynamics among instrument leaders, reagent specialists, and platform innovators shaping partnerships, validation services, and long-term procurement decisions

Competitive dynamics in the viral detection and quantification ecosystem reflect a mix of established instrument providers, reagent specialists, and emerging platform innovators. Leading instrument makers continue to invest in platform convergence, integrating molecular, sequencing, and immunoassay modalities to offer broader analytical footprints that appeal to both research and regulated manufacturing customers. At the same time, specialized reagent and kit suppliers focus on formulation consistency, lot control, and regulatory documentation to support validated workflows in GMP environments. Startups and scale-ups are pushing boundaries with CRISPR-based assays, nanopore sequencing improvements, and software-driven analytics that promise faster problem resolution and more actionable datasets.

Partnerships between hardware vendors, reagent manufacturers, and software developers are increasingly common, enabling end-to-end solutions that reduce complexity for end users. Strategic alliances with contract research organizations and contract development and manufacturing organizations also facilitate hands-on validation work and accelerate adoption in commercial manufacturing settings. Vendors that provide comprehensive validation packages, responsive technical support, and cloud-enabled data management often gain a competitive edge when customers evaluate total cost of ownership alongside long-term regulatory commitments.

Ultimately, companies that balance platform performance with serviceability, regulatory support, and supply continuity are best positioned to win long-term engagements. Providers that demonstrate responsiveness to change control requests, offer flexible supply arrangements, and invest in interoperable software ecosystems will be more successful in meeting the evolving needs of biomanufacturing stakeholders.

Concrete, high-impact recommendations for biomanufacturing leaders to strengthen assay validation, supplier diversification, automation interoperability, and regulatory data integrity

Industry leaders should prioritize a set of actionable initiatives to strengthen analytical robustness, supply resilience, and regulatory preparedness across viral detection and quantification programs. First, instituting cross-functional governance that coordinates quality, manufacturing, and analytical development teams will reduce silos and accelerate decision-making for assay selection, change control, and technical transfers. Embedding subject matter experts in validation planning early ensures assay performance criteria are aligned with release requirements and mitigates downstream surprises.

Second, organizations should diversify qualified supplier lists and pursue redundancy for critical reagents and consumables while developing clear requalification pathways to minimize production disruptions. Strategic inventory governance, combined with scenario-based stress testing of supplier continuity, can reduce operational risk without inflating carrying costs. Third, investing in platform interoperability and modular automation reduces friction when swapping instruments or reagent formats, enabling more agile responses to supply shocks or regulatory changes. Ensuring data integrity through validated software, robust audit trails, and standardized reporting templates will further enhance regulatory confidence and inspection readiness.

Finally, cultivating partnerships with external laboratories and contract organizations for surge capacity, and pursuing incremental adoption of high-sensitivity techniques such as digital PCR and targeted sequencing for critical release assays, will improve sensitivity and diagnostic resolution. Executed together, these recommendations create a resilient, compliant, and efficient analytical foundation that supports accelerated program development while safeguarding product quality.

A rigorous mixed-methods research approach combining stakeholder interviews, technical literature synthesis, regulatory alignment, and scenario-based supply chain analysis

The research methodology underpinning this analysis integrates a structured mix of qualitative and quantitative evidence to deliver a robust, operationally relevant perspective. Primary inputs were gathered through targeted interviews with laboratory directors, quality assurance leaders, procurement managers, and technical subject matter experts who provided insights into platform performance, validation challenges, and supplier dynamics. These firsthand accounts were synthesized to identify common pain points and adoption drivers across different end users and applications.

Secondary information was compiled from peer-reviewed literature, regulatory guidance documents, technical white papers, and publicly available product documentation to validate technological capabilities and typical use-case scenarios. The analysis also included scenario-based supply chain assessments to evaluate the potential operational implications of tariff changes and supplier disruptions, informed by industry-standard supply continuity practices. Analytical rigor was maintained through cross-validation of qualitative findings against documented product specifications, regulatory expectations, and common validation protocols used in regulated environments.

Throughout the research cycle, emphasis was placed on transparency of assumptions, traceable evidence trails for assertions, and alignment with practical implementation constraints faced by biomanufacturing organizations. This mixed-methods approach ensures that the conclusions and recommendations are both evidence-based and directly applicable to operational decision-making.

A conclusive synthesis emphasizing how integrated detection strategies, supplier resilience, and advanced analytics will determine biomanufacturing success and regulatory readiness

In conclusion, viral detection and quantification are no longer ancillary activities but core elements of biomanufacturing quality and operational strategy. The integration of sensitive molecular tools, automated workflows, and advanced analytics is delivering tangible improvements in contamination control, batch release processes, and regulatory traceability. At the same time, trade policy developments and supply chain complexity require proactive supplier qualification, flexible validation planning, and investment in interoperable platforms to sustain uninterrupted operations.

Organizations that adopt a strategic approach-combining cross-functional governance, diversified procurement, targeted adoption of high-sensitivity techniques, and validated data management systems-will be better positioned to manage risk and accelerate product development cycles. As technologies continue to evolve, continuous learning, partnership-driven validation efforts, and scenario planning will be essential to maintaining both compliance and competitive advantage. Ultimately, the ability to translate analytical capability into robust manufacturing practice will determine which organizations consistently deliver high-quality biologics and advanced therapeutics to patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of digital PCR and next-generation sequencing to enhance viral load quantification accuracy across large-scale bioprocesses
  • 5.2. Adoption of AI-enabled real-time monitoring of viral clearance steps to mitigate biosafety risks during biomanufacturing
  • 5.3. Implementation of continuous flow bioreactors with inline viral detection sensors to optimize vaccine production scalability
  • 5.4. Regulatory harmonization efforts for global approval of novel rapid molecular assays in viral contamination monitoring
  • 5.5. Development of multiplexed CRISPR-based assays for simultaneous detection of multiple viral contaminants in biologics
  • 5.6. Advances in microfluidic-based point-of-care viral quantification platforms for decentralized biologics manufacturing oversight

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biomanufacturing Viral Detection & Quantification Market, by Product

  • 8.1. Instruments & Systems
    • 8.1.1. Crispr Detection Systems
    • 8.1.2. Digital Pcr Systems
    • 8.1.3. Immunoassay Analyzers
    • 8.1.4. Ngs Platforms
    • 8.1.5. Real Time Pcr Systems
    • 8.1.6. Thermal Cyclers
  • 8.2. Reagents & Kits
    • 8.2.1. Immunoassay Reagents
    • 8.2.2. Ngs Library Preparation Kits
    • 8.2.3. Pcr Master Mixes
    • 8.2.4. Rna Extraction Kits
    • 8.2.5. Sequencing Reagents
  • 8.3. Software & Services

9. Biomanufacturing Viral Detection & Quantification Market, by Technology

  • 9.1. Crispr Technology
  • 9.2. Immunoassay
    • 9.2.1. Chemiluminescent Immunoassay
    • 9.2.2. Elisa
    • 9.2.3. Lateral Flow Assay
  • 9.3. Next Generation Sequencing
    • 9.3.1. Illumina Sequencing
    • 9.3.2. Ion Torrent Sequencing
    • 9.3.3. Nanopore Sequencing
  • 9.4. Polymerase Chain Reaction
    • 9.4.1. Conventional Pcr
    • 9.4.2. Digital Pcr
    • 9.4.3. Real-Time Pcr

10. Biomanufacturing Viral Detection & Quantification Market, by Application

  • 10.1. Gene Therapy Quality Control
  • 10.2. Research Applications
  • 10.3. Vaccine Development
  • 10.4. Viral Load Monitoring
  • 10.5. Viral Safety Testing

11. Biomanufacturing Viral Detection & Quantification Market, by End User

  • 11.1. Academic & Research Institutions
  • 11.2. Contract Research Organizations
  • 11.3. Diagnostic Laboratories
  • 11.4. Hospitals & Clinics
  • 11.5. Pharmaceutical & Biotechnology Companies

12. Biomanufacturing Viral Detection & Quantification Market, by Sample Type

  • 12.1. Blood & Plasma
  • 12.2. Environmental Samples
  • 12.3. Respiratory Samples
  • 12.4. Tissue Samples

13. Biomanufacturing Viral Detection & Quantification Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biomanufacturing Viral Detection & Quantification Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biomanufacturing Viral Detection & Quantification Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.2. Danaher Corporation
    • 16.3.3. Merck KGaA
    • 16.3.4. Roche Holding AG
    • 16.3.5. QIAGEN N.V.
    • 16.3.6. Illumina, Inc.
    • 16.3.7. Agilent Technologies, Inc.
    • 16.3.8. Bio-Rad Laboratories, Inc.
    • 16.3.9. PerkinElmer, Inc.
    • 16.3.10. Sartorius AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR DETECTION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR DETECTION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR DETECTION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR DETECTION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR DETECTION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR DETECTION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL TIME PCR SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL TIME PCR SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL TIME PCR SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL TIME PCR SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL TIME PCR SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL TIME PCR SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY THERMAL CYCLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY THERMAL CYCLERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY THERMAL CYCLERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY THERMAL CYCLERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY THERMAL CYCLERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY THERMAL CYCLERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS LIBRARY PREPARATION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS LIBRARY PREPARATION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS LIBRARY PREPARATION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS LIBRARY PREPARATION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS LIBRARY PREPARATION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS LIBRARY PREPARATION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PCR MASTER MIXES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PCR MASTER MIXES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PCR MASTER MIXES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PCR MASTER MIXES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PCR MASTER MIXES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PCR MASTER MIXES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RNA EXTRACTION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RNA EXTRACTION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RNA EXTRACTION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RNA EXTRACTION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RNA EXTRACTION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RNA EXTRACTION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SEQUENCING REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SEQUENCING REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SEQUENCING REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SEQUENCING REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SEQUENCING REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SEQUENCING REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ION TORRENT SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ION TORRENT SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ION TORRENT SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ION TORRENT SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ION TORRENT SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ION TORRENT SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NANOPORE SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NANOPORE SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NANOPORE SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NANOPORE SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NANOPORE SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NANOPORE SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GENE THERAPY QUALITY CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GENE THERAPY QUALITY CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GENE THERAPY QUALITY CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GENE THERAPY QUALITY CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GENE THERAPY QUALITY CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GENE THERAPY QUALITY CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VACCINE DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VACCINE DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VACCINE DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VACCINE DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL LOAD MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL LOAD MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL LOAD MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL LOAD MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL LOAD MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL LOAD MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL SAFETY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL SAFETY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL SAFETY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL SAFETY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL SAFETY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL SAFETY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (